Polymerase-chain-reaction-based semi-quantification of hepatitis D viraemia in patients treated with high doses of α2b interferon

P. Dény, G. Fattovich, F. Le Gal, G. Giustina, C. Lecot, G. Morsica, H. Poinsot, A. Alberti, C. Bréchot

Research output: Contribution to journalArticle

Abstract

To study the antiviral efficacy of high doses of α2b interferon (α2b-IFN) for chronic hepatitis D treatment, we used polymerase-chain-reaction(PCR)-based semi-quantitative detection of HDV RNA. The semiquantification method used was based on the appearance of a positive amplification signal as a function of the number of PCR cycles. By amplifying dilutions (10-1 - 10-8) of an HDV-positive woodchuck liver RNA, we confirmed that exponential amplification efficacy occurred at between 20 and 30 cycles. Positive signals were observed from dilution 10-2 (gel electrophoresis after 20 cycles of PCR) to dilution 10-7 (hybridization after 30 cycles of PCR). To characterize the HDV RNA level in sera of 8 patients treated with α2b-IFN (10 MU/3 times a week) for 1 year, we extracted RNA from serum samples taken every 6 months. All samples were amplified in parallel for 20 and 30 PCR cycles. Analysis of HDV cDNA after ethidium bromide/agarose gel electrophoresis and after molecular hybridization (100 times more sensitive than gel analysis), enabled us to grade the signals observed from negative to positive as 1 +, 2 +, 3 + and 4 +, with all results being positive. Three types of evolution of HDV viraemia were evidenced among the 8 treated patients. HDV replication continued to occur at a high level at the 6th and 12th month in 2 patient sera. For 2 other patients, an HDV RNA decrease or disappearance was evidenced in the serum at the 6th month; however, viral replication recurred at a higher level at the 12th month. Finally, the HDV genome was no longer detected during therapy in the final 4 patients. These results were compared to clinical and biological data. The level of alanine aminotransferase (ALAT) paralleled HDV RNA gradation in 15 samples from 5 patients. However, in 2 patients, HDV-RNA was negative at the 6th month, before the normalization of ALAT. In the serum of another patient, HDV RNA was still detected when the ALAT level was normal. This study shows the usefulness of HDV PCR in appreciating the potential benefits of α2b-IFN during chronic hepatitis D infection. However, long-term improvement was present in only one patient in whom a negative HDV PCR results was associated with loss of HBs-Ag. This simple approach uses complementary results of only two PCR experiments and quickly provides information on the level of HDV viraemia.

Original languageEnglish
Pages (from-to)287-295
Number of pages9
JournalResearch in Virology
Volume145
Issue numberC
DOIs
Publication statusPublished - 1994

Fingerprint

Hepatitis D
Viremia
Interferons
Polymerase Chain Reaction
RNA
Chronic Hepatitis D
Alanine Transaminase
Serum
Gels
Marmota
Ethidium
Agar Gel Electrophoresis
Antiviral Agents
Electrophoresis
Complementary DNA
Genome

Keywords

  • Delta virus, Viraemia, Interferon
  • Hepatitis, HDV
  • Therapy, α2b-IFN, Quantification, PCR

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Polymerase-chain-reaction-based semi-quantification of hepatitis D viraemia in patients treated with high doses of α2b interferon. / Dény, P.; Fattovich, G.; Le Gal, F.; Giustina, G.; Lecot, C.; Morsica, G.; Poinsot, H.; Alberti, A.; Bréchot, C.

In: Research in Virology, Vol. 145, No. C, 1994, p. 287-295.

Research output: Contribution to journalArticle

Dény, P. ; Fattovich, G. ; Le Gal, F. ; Giustina, G. ; Lecot, C. ; Morsica, G. ; Poinsot, H. ; Alberti, A. ; Bréchot, C. / Polymerase-chain-reaction-based semi-quantification of hepatitis D viraemia in patients treated with high doses of α2b interferon. In: Research in Virology. 1994 ; Vol. 145, No. C. pp. 287-295.
@article{3d0714ca8a6245f29c9990c6e1e337db,
title = "Polymerase-chain-reaction-based semi-quantification of hepatitis D viraemia in patients treated with high doses of α2b interferon",
abstract = "To study the antiviral efficacy of high doses of α2b interferon (α2b-IFN) for chronic hepatitis D treatment, we used polymerase-chain-reaction(PCR)-based semi-quantitative detection of HDV RNA. The semiquantification method used was based on the appearance of a positive amplification signal as a function of the number of PCR cycles. By amplifying dilutions (10-1 - 10-8) of an HDV-positive woodchuck liver RNA, we confirmed that exponential amplification efficacy occurred at between 20 and 30 cycles. Positive signals were observed from dilution 10-2 (gel electrophoresis after 20 cycles of PCR) to dilution 10-7 (hybridization after 30 cycles of PCR). To characterize the HDV RNA level in sera of 8 patients treated with α2b-IFN (10 MU/3 times a week) for 1 year, we extracted RNA from serum samples taken every 6 months. All samples were amplified in parallel for 20 and 30 PCR cycles. Analysis of HDV cDNA after ethidium bromide/agarose gel electrophoresis and after molecular hybridization (100 times more sensitive than gel analysis), enabled us to grade the signals observed from negative to positive as 1 +, 2 +, 3 + and 4 +, with all results being positive. Three types of evolution of HDV viraemia were evidenced among the 8 treated patients. HDV replication continued to occur at a high level at the 6th and 12th month in 2 patient sera. For 2 other patients, an HDV RNA decrease or disappearance was evidenced in the serum at the 6th month; however, viral replication recurred at a higher level at the 12th month. Finally, the HDV genome was no longer detected during therapy in the final 4 patients. These results were compared to clinical and biological data. The level of alanine aminotransferase (ALAT) paralleled HDV RNA gradation in 15 samples from 5 patients. However, in 2 patients, HDV-RNA was negative at the 6th month, before the normalization of ALAT. In the serum of another patient, HDV RNA was still detected when the ALAT level was normal. This study shows the usefulness of HDV PCR in appreciating the potential benefits of α2b-IFN during chronic hepatitis D infection. However, long-term improvement was present in only one patient in whom a negative HDV PCR results was associated with loss of HBs-Ag. This simple approach uses complementary results of only two PCR experiments and quickly provides information on the level of HDV viraemia.",
keywords = "Delta virus, Viraemia, Interferon, Hepatitis, HDV, Therapy, α2b-IFN, Quantification, PCR",
author = "P. D{\'e}ny and G. Fattovich and {Le Gal}, F. and G. Giustina and C. Lecot and G. Morsica and H. Poinsot and A. Alberti and C. Br{\'e}chot",
year = "1994",
doi = "10.1016/S0923-2516(07)80033-1",
language = "English",
volume = "145",
pages = "287--295",
journal = "Research in Virology",
issn = "0923-2516",
publisher = "Elsevier BV",
number = "C",

}

TY - JOUR

T1 - Polymerase-chain-reaction-based semi-quantification of hepatitis D viraemia in patients treated with high doses of α2b interferon

AU - Dény, P.

AU - Fattovich, G.

AU - Le Gal, F.

AU - Giustina, G.

AU - Lecot, C.

AU - Morsica, G.

AU - Poinsot, H.

AU - Alberti, A.

AU - Bréchot, C.

PY - 1994

Y1 - 1994

N2 - To study the antiviral efficacy of high doses of α2b interferon (α2b-IFN) for chronic hepatitis D treatment, we used polymerase-chain-reaction(PCR)-based semi-quantitative detection of HDV RNA. The semiquantification method used was based on the appearance of a positive amplification signal as a function of the number of PCR cycles. By amplifying dilutions (10-1 - 10-8) of an HDV-positive woodchuck liver RNA, we confirmed that exponential amplification efficacy occurred at between 20 and 30 cycles. Positive signals were observed from dilution 10-2 (gel electrophoresis after 20 cycles of PCR) to dilution 10-7 (hybridization after 30 cycles of PCR). To characterize the HDV RNA level in sera of 8 patients treated with α2b-IFN (10 MU/3 times a week) for 1 year, we extracted RNA from serum samples taken every 6 months. All samples were amplified in parallel for 20 and 30 PCR cycles. Analysis of HDV cDNA after ethidium bromide/agarose gel electrophoresis and after molecular hybridization (100 times more sensitive than gel analysis), enabled us to grade the signals observed from negative to positive as 1 +, 2 +, 3 + and 4 +, with all results being positive. Three types of evolution of HDV viraemia were evidenced among the 8 treated patients. HDV replication continued to occur at a high level at the 6th and 12th month in 2 patient sera. For 2 other patients, an HDV RNA decrease or disappearance was evidenced in the serum at the 6th month; however, viral replication recurred at a higher level at the 12th month. Finally, the HDV genome was no longer detected during therapy in the final 4 patients. These results were compared to clinical and biological data. The level of alanine aminotransferase (ALAT) paralleled HDV RNA gradation in 15 samples from 5 patients. However, in 2 patients, HDV-RNA was negative at the 6th month, before the normalization of ALAT. In the serum of another patient, HDV RNA was still detected when the ALAT level was normal. This study shows the usefulness of HDV PCR in appreciating the potential benefits of α2b-IFN during chronic hepatitis D infection. However, long-term improvement was present in only one patient in whom a negative HDV PCR results was associated with loss of HBs-Ag. This simple approach uses complementary results of only two PCR experiments and quickly provides information on the level of HDV viraemia.

AB - To study the antiviral efficacy of high doses of α2b interferon (α2b-IFN) for chronic hepatitis D treatment, we used polymerase-chain-reaction(PCR)-based semi-quantitative detection of HDV RNA. The semiquantification method used was based on the appearance of a positive amplification signal as a function of the number of PCR cycles. By amplifying dilutions (10-1 - 10-8) of an HDV-positive woodchuck liver RNA, we confirmed that exponential amplification efficacy occurred at between 20 and 30 cycles. Positive signals were observed from dilution 10-2 (gel electrophoresis after 20 cycles of PCR) to dilution 10-7 (hybridization after 30 cycles of PCR). To characterize the HDV RNA level in sera of 8 patients treated with α2b-IFN (10 MU/3 times a week) for 1 year, we extracted RNA from serum samples taken every 6 months. All samples were amplified in parallel for 20 and 30 PCR cycles. Analysis of HDV cDNA after ethidium bromide/agarose gel electrophoresis and after molecular hybridization (100 times more sensitive than gel analysis), enabled us to grade the signals observed from negative to positive as 1 +, 2 +, 3 + and 4 +, with all results being positive. Three types of evolution of HDV viraemia were evidenced among the 8 treated patients. HDV replication continued to occur at a high level at the 6th and 12th month in 2 patient sera. For 2 other patients, an HDV RNA decrease or disappearance was evidenced in the serum at the 6th month; however, viral replication recurred at a higher level at the 12th month. Finally, the HDV genome was no longer detected during therapy in the final 4 patients. These results were compared to clinical and biological data. The level of alanine aminotransferase (ALAT) paralleled HDV RNA gradation in 15 samples from 5 patients. However, in 2 patients, HDV-RNA was negative at the 6th month, before the normalization of ALAT. In the serum of another patient, HDV RNA was still detected when the ALAT level was normal. This study shows the usefulness of HDV PCR in appreciating the potential benefits of α2b-IFN during chronic hepatitis D infection. However, long-term improvement was present in only one patient in whom a negative HDV PCR results was associated with loss of HBs-Ag. This simple approach uses complementary results of only two PCR experiments and quickly provides information on the level of HDV viraemia.

KW - Delta virus, Viraemia, Interferon

KW - Hepatitis, HDV

KW - Therapy, α2b-IFN, Quantification, PCR

UR - http://www.scopus.com/inward/record.url?scp=0028149949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028149949&partnerID=8YFLogxK

U2 - 10.1016/S0923-2516(07)80033-1

DO - 10.1016/S0923-2516(07)80033-1

M3 - Article

C2 - 7839006

AN - SCOPUS:0028149949

VL - 145

SP - 287

EP - 295

JO - Research in Virology

JF - Research in Virology

SN - 0923-2516

IS - C

ER -